Q32 Bio (DB0) Price & Analysis

3 Followers

DB0 Stock Chart & Stats

€4.76

-€0.02(-0.60%)

At close: Jan 08 4:00 PM EST

€4.76

-€0.02(-0.60%)

Day’s Range― - ―

52-Week Range€1.35 - €12.55

Previous CloseN/A

Volume0.00

Average Volume (3M)7.00

Market Cap

€233.08M

Enterprise Value€125.18M

Total Cash (Recent Filing)€50.75M

Total Debt (Recent Filing)€13.65M

Price to Earnings (P/E)8.0

Beta0.23

Next Earnings

Aug 06, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.68

Shares Outstanding23,681,416

10 Day Avg. Volume0

30 Day Avg. Volume7

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.97

Price to Sales (P/S)0.76

P/FCF Ratio-1.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€34.02

Price Target Upside614.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.59

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical-stage Asset Efficacy & SafetyDurable clinical proof-of-concept and a clean safety profile de-risks bempikibart for a registration-directed program. Positive biomarker and off-drug durability signals support broader T-cell mediated indications and make future partnerships or label expansion more attainable over 2–6 months.

Strengthened Financing And Balance SheetA meaningful $55M institutional placement plus termination of a ~$6.8M loan materially improves near-term liquidity and simplifies capital structure. This reduces immediate financing pressure and supports ongoing Phase 2/registration activities, lowering short-term dilution risk and enabling execution.

Improved Trailing Profitability MarginsA pronounced improvement in TTM margins signals better operating leverage and cost control versus prior loss periods. If sustained, these margins increase the firm's ability to allocate cash to R&D and reduce incremental financing needs, strengthening long-term operational credibility.

Bears Say

Negative Cash GenerationConsistent negative operating and free cash flow means the business is not self-funding and remains dependent on external capital. Over a multi-month horizon this heightens execution risk for clinical programs and increases the probability of additional financings or constrained R&D pacing.

Flat Revenue And No Commercial SalesFlat revenue and absence of commercial product sales leave the company reliant on trial-readouts and financing events for value realization. This structural lack of recurring cash inflows makes margins and capital needs volatile and magnifies the impact of any clinical setbacks.

Ongoing Dependence On Equity FinancingRepeated use of ATM capacity, a $55M private placement and a new $200M offering indicate continued reliance on capital markets. This structural funding dependence raises dilution risk, requires favorable market access, and can constrain strategic flexibility if capital conditions tighten.

Q32 Bio News

Q32 Bio announces $200M common stock offering

Q32 Bio (QTTB) announced that it has commenced an underwritten public offering of $200M of shares of its...

20h ago

QTTB

Q32 Bio price target raised to $36 from $14 at Mizuho

Mizuho analyst Joseph Catanzaro raised the firm’s price target on Q32 Bio (QTTB) to $36 from $14 and...

22h ago

QTTB

Midday Fly By: Apple sues OpenAI, MGM in talks with Diller’s People

The major averages were broadly lower as rising geopolitical tensions and another bout of semiconductor selling weigh on...

1d ago

Q32 Bio price target raised to $40 from $20 at Oppenheimer

Oppenheimer raised the firm’s price target on Q32 Bio (QTTB) to $40 from $20 and keeps an Outperform...

1d ago

QTTB

Q32 Bio upgraded to Overweight at Wells Fargo after alopecia areata study data

As previously reported, Wells Fargo analyst Derek Archila upgraded Q32 Bio (QTTB) to Overweight from Equal Weight with...

1d ago

QTTB

Q32 Bio upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Q32 Bio (QTTB) to Overweight from Equal Weight with a $66 price target Published first...

1d ago

QTTB

Q32 Bio reports 36-week topline results from Part B of the SIGNAL-AA trial

Q32 Bio (QTTB) announced 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating...

1d ago

QTTB

Q32 Bio files $300M mixed securities shelf

16:15 EDT Q32 Bio (QTTB) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

19d ago

QTTB

Five new option listings and two option delistings on June 24th

New option listings for June 24th include Echo/Echo Echostar Corporation (ECHO), Gloo Holdings Inc (GLOO), Q32 Bio Inc...

20d ago

GLOO

QTTB

Q32 Bio Reports Positive Phase 2a Alopecia Areata Results

An announcement from Q32 Bio ( ($QTTB) ) is now available. On July 13, 2026, Q32 Bio announced...

23h ago

QTTB

Q32 Bio Reports Positive Alopecia Phase 2a Data

Q32 Bio ( ($QTTB) ) has shared an update. On July 13, 2026, Q32 Bio reported positive 36-week...

1d ago

QTTB

Q32 Bio Shareholders Back Directors, Auditor and Executive Pay

Q32 Bio ( ($QTTB) ) has provided an update. At Q32 Bio Inc.’s 2026 Annual Meeting of Stockholders,...

28d ago

QTTB

3 Penny Stocks to Watch Now, 5/28/26

Astrotech Corporation ($ASTC), Momentus ($MNTS), and Q32 Bio ($QTTB) are the three penny stocks to watch on May...

2M ago

ASTC

MNTS

Q32 Bio Raises $55 Million in Private Placement

An announcement from Q32 Bio ( ($QTTB) ) is now available. On May 26, 2026, Q32 Bio Inc....

2M ago

QTTB

DB0 FAQ

What was Q32 Bio Inc’s price range in the past 12 months?

Q32 Bio Inc lowest stock price was €1.35 and its highest was €12.55 in the past 12 months.

What is Q32 Bio Inc’s market cap?

Q32 Bio Inc’s market cap is €233.08M.

When is Q32 Bio Inc’s upcoming earnings report date?

Q32 Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.

How were Q32 Bio Inc’s earnings last quarter?

Q32 Bio Inc released its earnings results on May 05, 2026. The company reported -€0.474 earnings per share for the quarter, beating the consensus estimate of -€0.597 by €0.123.

Is Q32 Bio Inc overvalued?

According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Q32 Bio Inc pay dividends?

Q32 Bio Inc does not currently pay dividends.

What is Q32 Bio Inc’s EPS estimate?

Q32 Bio Inc’s EPS estimate is -0.48.

How many shares outstanding does Q32 Bio Inc have?

Q32 Bio Inc has 23,681,416 shares outstanding.

What happened to Q32 Bio Inc’s price movement after its last earnings report?

Q32 Bio Inc reported an EPS of -€0.474 in its last earnings report, beating expectations of -€0.597. Following the earnings report the stock price went up 0.429%.

Which hedge fund is a major shareholder of Q32 Bio Inc?

Currently, no hedge funds are holding shares in DE:DB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Q32 Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

230.68%

Trailing 12-Months

Asset Growth

-19.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Q32 Bio Inc

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Q32 Bio (DB0) Earnings & Revenues

Historic Earnings Reports

DB0 Stock 12 Month Forecast

Average Price Target

€34.02

▲(614.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","29":"€29","58":"€58","14.5":"€14.5","43.5":"€43.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.946685280000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.021728100000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€34.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.413741040000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,14.5,29,43.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,14.500514252307694,18.121028504615385,21.741542756923078,25.36205700923077,28.98257126153846,32.60308551384615,36.223599766153846,39.84411401846154,43.46462827076923,47.085142523076925,50.70565677538462,54.32617102769231,{"y":57.946685280000004,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,12.660132930769231,14.440265861538462,16.220398792307694,18.000531723076925,19.780664653846156,21.560797584615386,23.340930515384617,25.121063446153848,26.90119637692308,28.68132930769231,30.461462238461543,32.24159516923077,{"y":34.021728100000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,10.921057003076925,10.962114006153847,11.00317100923077,11.044228012307693,11.085285015384617,11.12634201846154,11.167399021538463,11.208456024615385,11.24951302769231,11.290570030769231,11.331627033846155,11.372684036923077,{"y":11.413741040000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.21,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.588,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.395,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >